KYMR

NASDAQ 已收盘

Kymera Therapeutics

119.39 USD
▼-1.74-1.44%
盘后 125.40 0.00%
2026-11-19
市值
$9.87B
市盈率
—
EPS
-3.62
股息率
—
52 周区间
63.69 – 142.92
成交量
723.17K
Beta
2.03
目标价
145.22
52W 低 63.6952W 高 142.92
价格走势

公司简介

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid...